Cerus achieved record product revenue in Q4 2025, driven by strong demand in EMEA and U.S. IFC sales. The company narrowed its GAAP net loss and maintained positive non-GAAP adjusted EBITDA, while generating positive operating cash flow for the quarter.

Cerus Corporation reported a robust second quarter in 2025, achieving record product revenue of $52.4 million, a 16% increase year-over-year. The company also posted positive non-GAAP adjusted EBITDA of $0.9 million and narrowed its net loss attributable to Cerus. This strong performance led to an upward revision of full-year 2025 product revenue guidance.

Cerus Corporation delivered a strong start to 2025, with first quarter product revenue increasing by 13% to $43.2 million and total revenue reaching $48.9 million. The company also achieved a positive non-GAAP adjusted EBITDA and reiterated its full-year 2025 product revenue guidance.

Cerus Corporation delivered strong financial results for the fourth quarter and full year 2024, exceeding its stated goals. Product revenue grew significantly, driven by momentum in its platelets business and increasing demand for its IFC product. The company achieved positive non-GAAP adjusted EBITDA and generated substantial positive operating cash flows, demonstrating robust financial execution.

Cerus Corporation reported a 16% increase in product revenue for the third quarter of 2024 compared to the previous year, driven by growth in the platelets business, particularly in North America. The company narrowed its GAAP net loss and generated positive non-GAAP adjusted EBITDA. Cerus raised its full-year 2024 product revenue guidance to $177 million to $179 million.

Cerus Corporation reported a strong second quarter in 2024, driven by growth in the platelets business, particularly in North America, and achieved positive operating cash flows for the second straight quarter. The company narrowed its GAAP net loss and generated non-GAAP adjusted EBITDA of $0.8 million. Given expectations for continued momentum, the company is raising its full-year 2024 product revenue guidance.

Cerus Corporation announced financial results for the first quarter ended March 31, 2024, with a 13% increase in total revenue compared to the prior year quarter. Product revenue increased by 24%, driven by strong sales of the INTERCEPT Blood System for Platelets in North America. The company is reiterating its full-year 2024 annual product revenue guidance range of $172 million to $175 million.

Cerus Corporation announced its Q4 and full-year 2023 financial results, highlighting sequential revenue growth in the fourth quarter driven by North American sales. The company narrowed its GAAP net loss attributable to Cerus Corporation to $1.3 million for the fourth quarter and achieved its goal of adjusted EBITDA breakeven for the fourth quarter. Cerus is reiterating its full-year 2024 product revenue guidance range of $172-175 Million.

Cerus Corporation reported total revenue of $47.3 million for Q3 2023, consisting of $39.8 million in product revenue and $7.5 million in government contract revenue. The company is adjusting its full-year 2023 product revenue guidance to a range of $155 million to $158 million.

Cerus Corporation reported a total revenue of $47.7 million for Q2 2023, consisting of $38.9 million in product revenue and $8.9 million in government contract revenue. The company is adjusting its full-year 2023 annual product revenue guidance to the range of $160 million to $165 million.

Cerus Corporation reported a total revenue of $38.5 million for Q1 2023, which includes product revenue of $31.0 million and government contract revenue of $7.5 million. The company is reiterating its full-year 2023 annual product revenue guidance range of $165 million to $170 million.

Cerus Corporation announced record fourth-quarter financial results, with product revenue growing 10% year-over-year to $44.0 million. The company is reiterating its full-year 2023 annual product revenue guidance range of $165 million to $170 million.

Cerus Corporation reported a 10% increase in total revenue for Q3 2022, reaching $46.3 million. Product revenue also grew by 10% year-over-year to $39.6 million despite a 6% foreign exchange headwind. The company's net loss improved by $3.9 million compared to the prior year period, and cash, cash equivalents, and short-term investments totaled $103.8 million.

Cerus Corporation announced record product revenue for the second quarter of 2022, with total revenue reaching $47.6 million, a 26% increase year-over-year. The company reiterated its full-year 2022 product revenue guidance of $160-165 million.

Cerus Corporation reported a strong first quarter with a 46% increase in total revenue, driven by increased sales of INTERCEPT platelet kits in the U.S. The company increased its full-year product revenue guidance from $157-164 million to $160-165 million.

Cerus Corporation announced record fourth quarter and full-year 2021 financial results, with total revenue of $50.1 million, a 49% increase compared to the prior year period, and product revenue of $39.9 million, a 41% increase compared to the prior year period.

Cerus Corporation reported a 44% increase in total revenue for Q3 2021, reaching $42.1 million, with product revenue growing by 53% to $36.1 million, driven by U.S. adoption of INTERCEPT platelets. The company raised its full-year product revenue guidance to $127-129 million.

Cerus Corporation reported a 41% increase in total revenue, reaching $37.8 million in Q2 2021, driven by a 46% increase in product revenue to $31.5 million. The company raised its full-year product revenue guidance to $118-122 million.

Cerus Corporation announced its first quarter 2021 financial results, reporting a 20% increase in total revenue compared to the prior year period. Product revenue grew due to increased demand for INTERCEPT platelet products in the U.S. The company also raised its full year product revenue guidance to $110 million to $114 million.

Cerus Corporation reported record total fourth quarter revenues of $33.6 million. Product revenue during the fourth quarter of 2020 was $28.2 million, compared to $20.9 million during the same period in 2019. Government contract revenue primarily from the BARDA agreement was $5.4 million during the fourth quarter of 2020, compared to $5.6 million during the same period in 2019. Net loss for the fourth quarter of 2020 was $14.4 million, compared to a net loss of $16.9 million for the fourth quarter of 2019.

Cerus Corporation announced record third quarter 2020 results with a total revenue of $29.2 million. The company narrowed its full year product revenue guidance to a range of $89 million to $91 million. The company had cash, cash equivalents, and short-term investments of $135.1 million at September 30, 2020.

Cerus Corporation announced record second-quarter results, with total revenue reaching $26.8 million. Product revenue was $21.5 million, driven by strong platelet kit sales in the U.S. and plasma and illuminator sales in EMEA. The company reaffirmed its full-year product revenue guidance of $89 million to $93 million.

Cerus Corporation reported a total revenue of $24.6 million for Q1 2020, with product revenue reaching $18.6 million, a 6% increase year-over-year. The company reaffirmed its full-year product revenue guidance of $89 million to $93 million. Net loss for the quarter was $16.5 million, or $0.10 per diluted share, improved from a net loss of $18.8 million, or $0.14 per diluted share, in Q1 2019.

Cerus Corporation announced record fourth quarter product revenue of $20.9 million, a 27% increase compared to the prior year quarter. Total fourth quarter revenue was $26.5 million. The company provided 2020 annual product revenue guidance of $89 million to $93 million.